Psychedelics
Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications
Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced the filing of three distinct U.S. Provisional Patent applications with the U.S. Patent and Trademark Office (“USPTO”) pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin. “Each of these […]
Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange
Entheon Biomedical Corp. (formerly, MPV Exploration Inc.) (CSE: ENBI) (“Entheon” or the “Company”) is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “ENBI”. Timothy Ko, CEO of Entheon, stated: “We are thrilled by the opportunity that […]
NeonMind Obtains Health Canada Approval to Advance Psilocybin Research
Vancouver, British Columbia–(Newsfile Corp. – November 12, 2020) – Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant“) or (the “Company“) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) has obtained Health Canada approval to advance its preclinical trial on psilocybin-based research (the “Trial“). Figure 1: NeonMind […]
Toronto, Ontario–(Newsfile Corp. – November 10, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), is pleased to announce it has entered into a non-binding letter of intent to acquire SR Wholesale B.V. (“SR Wholesale“), one of the Netherlands’ premiere distributors for quality Truffles, CBD products, […]
Cybin Goes Public on the NEO Exchange
The direct and indirect costs of mental health disorders add up to more than $2.5 trillion worldwide, according to the National Centre for Biotechnology Information. A growing body of research suggests that psychedelics could play a major role in the treatment of these disorders. Not surprisingly, a psychedelics industry has emerged with a number […]
Cybin Goes Public on NEO Exchange
Cybin Inc., a leading Toronto-based biotech and life sciences company focused on psychedelic pharmaceutical therapies, participates in a digital market open to celebrate its debut on the global public markets today. Cybin is now trading on the NEO Exchange under the symbol NEO:CYBN. (Photo: Business Wire) November 10, 2020 10:45 AM Eastern Standard Time TORONTO–(BUSINESS […]
CB Therapeutics: Producing Rare Cannabinoid & Psychedelic Molecules at Scale
The cannabis industry has evolved from the legalization of dried cannabis to an increasingly detailed understanding of individual cannabinoids. While THC and CBD are the two most common, researchers are increasingly interested in CBC, THCV and other rare cannabinoids that could have specific and desirable effects on certain medical indications. The problem is that these […]
Following the passage of all nine statewide ballot measures to reform drug policies across the United States, including the first measure to decriminalize drug possession in Oregon with a Portugal-inspired approach, the Multidisciplinary Association for Psychedelic Studies (MAPS) releases the following statements: Natalie Ginsberg, M.S.W., Director of Policy & Advocacy Yesterday, Oregon voters crowned an […]
Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), one of the leaders in the development and delivery of psychedelic therapies, announced today that it is in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies following the passage of Measure 109 (“Measure 109” or the […]
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. (“Pilz”), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have complete and sole ownership of the Drug Master […]
MagicMed verkürzt die Fristen für die Kommerzialisierung durch Universitätsvertrag
Die meisten Pharma- und Biotech-Investoren sind mit langen Kommerzialisierungsfristen vertraut, aber es gibt einige Möglichkeiten, diese zu verkürzen. Beispielsweise bietet die Food and Drug Administration für bestimmte Therapien, die auf lebensbedrohliche Erkrankungen abzielen, Bezeichnungen wie Fast Track, Durchbruchstherapie, beschleunigte Zulassung und Prioritätsprüfung an. MagicMed Industries Inc., ein Entwickler von lizenzierbaren psychedelischen molekularen Derivaten, verkürzte seinen […]
Entheon Biomedical Corp. (CSE: MPV) (formerly, MPV Exploration Inc.) (“Entheon” or the “Company“) is pleased to announce that further to its news releases dated July 2, 2020, September 10, 2020 and October 28, 2020, the Company has completed the previously announced business combination with Entheon Holdings Corp. (formerly, Entheon Biomedical Corp.) and has received final […]
Beckley Psytech appoints leading experts to Scientific Advisory Board
Beckley Psytech, the psychedelic medicine company, has appointed Joanna Neill, Professor of Psychopharmacology at the University of Manchester, and Dr Mike Emanuel, former Vice President of Global Clinical Operations at Johnson & Johnson, to its Scientific Advisory Board. As members of the Scientific Advisory Board, Neill and Emanuel will channel their expertise to guide and advise […]
MagicMed Shortcuts Commercialization Timeline with University Agreement
Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions. MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, […]
MindMed Announces the Completion of Phase I Study Measuring Dosing Effects of LSD
MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel’s Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials […]
CALGARY, Alberta, 30. Oktober 2020 /PRNewswire/ — MagicMed Industries Inc. („MagicMed” oder das „Unternehmen“) gibt freudig bekannt, dass es mit der University of Calgary einen Forschungsvertrag und einen Vertrag über die Nutzung der Räumlichkeiten („die Verträge”) abgeschlossen hat. Durch die Verträge erhält MagicMed weitere wissenschaftliche und Laborunterstützung, um die Entwicklung seiner Patentbibliothek für psychedelische Derivate, der Psybrary™, voranzubringen. […]
Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has signed on to support ground-breaking research with the MIND Foundation on a study on depression and psilocybin. Havn Life is donating […]
Pharmather Files for FDA Orphan Drug Designation for Ketamine in Neuropathic Pain
Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine […]
Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company“) is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter’s over-allotment option (the “Offering“). In connection with the Offering, the Company issued 27,381,500 units of the Company (the […]
Psyched Wellness Ltd. Adds Scientific Advisor Brian Tancowny
Psyched Wellness Ltd. (CSE: PSYC) (OTC Pink: DCNPF) (formerly Duncan Park Holdings Corporation) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of artisanal functional mushrooms, is pleased to announce that Brian Towncany has joined the advisory board to support the management team on the scientific side as the Company progresses […]
ATAI Life Sciences (“ATAI” or the “Company”), a global biotechnology company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that Neuronasal Inc. (“Neuronasal”) has completed its pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has been granted Investigational New Drug (IND) clearance by the […]
Field Trip Health Ltd. (CSE: FTRP) (OTC: FTRPF) (“Field Trip”), the leader in the development and delivery of psychedelic therapies, today provided an update on its in-vivo and in-vitro studies on FT-104, its lead drug candidate. Further to its announcement on September 29, 2020, confirming both the successful GLP synthesis of FT-104 and that FT-104 […]
CALGARY, AB, Oct. 30, 2020 – MagicMed Industries Inc. (“MagicMed” or the “Company“) is pleased to announce that it has entered into a Research Contract and a Facilities Use Agreement (“The Agreements”) with the University of Calgary. The Agreements provide MagicMed with further scientific and laboratory support to accelerate development of its psychedelic derivatives patent library, the Psybrary™. “The University of Calgary is excited […]
Wie groß ist die psychedelische Gelegenheit?
Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen und zwei Breakthrough Therapie Bezeichnungen, sind Unternehmen, die Kapital beschaffen, um die Multi-Milliarden-Dollar […]
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED’S GROWING PIPELINE OF PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIES NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 27, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the “Company“) is pleased to announce that further to its previously announced offering […]
Just How Big is the Psychedelics Opportunity?
The North American market for psychedelic drugs is projected to reach $6.85 billion by 2027, according to Data Bridge Market Research, which represents a 16.3% compound annual growth rate. After the approval of Johnson & Johnson’s (NYSE: JNJ) SPRAVATO nasal spray for treatment-resistant depression and two Breakthrough Therapy designations, there has been an explosion of […]
Delic Corp. Enters into Definitive Agreement for Reverse Takeover of Molystar Resources Inc.
Molystar Resources Inc. (“Molystar” or the “Company“), Delic Corp. (“Delic“), a Delaware-incorporated psychedelic-focused media, e-commerce and event company, and Eception Ventures Ltd. (“Eception“) are pleased to confirm, further to Molystar’s press release dated August 31, 2020 (the “Previous Press Release“), a business combination agreement (the “Proposed Transaction“) has been entered into among Molystar, Delic and […]
Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of […]
Mind Cure Health Inc. (CSE: MCUR) (“Mind Cure” or the “Corporation”) is pleased today to announce that it has entered into a non-binding letter of intent dated October 16, 2020 (the “LOI“), which sets out basic terms and conditions for the acquisition by Mind Cure of Ephiphany360, a proprietary cloud-based digital therapeutics platform for treating mental health. The […]
Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, announced today the opening of their Chicago center. Located at 325 West Huron Street, Suite 603, the Chicago location is the fourth Field Trip Health center to open this year, following Toronto, New York and […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Flora is building a connected, design-led collective, of plant-based wellness and lifestyle brands, that delivers the most compelling customer experiences in the world, one community at a time.
Cansortium is a US Based, vertically integrated cannabis company with a global mission: deliver the highest standards of cannabis care from nursery to lab to shelf.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
